[go: up one dir, main page]

SG11201805872SA - Chimeric antigen receptors targeting epidermal growth factor receptor variant iii - Google Patents

Chimeric antigen receptors targeting epidermal growth factor receptor variant iii

Info

Publication number
SG11201805872SA
SG11201805872SA SG11201805872SA SG11201805872SA SG11201805872SA SG 11201805872S A SG11201805872S A SG 11201805872SA SG 11201805872S A SG11201805872S A SG 11201805872SA SG 11201805872S A SG11201805872S A SG 11201805872SA SG 11201805872S A SG11201805872S A SG 11201805872SA
Authority
SG
Singapore
Prior art keywords
international
rule
factor receptor
epidermal growth
chimeric antigen
Prior art date
Application number
SG11201805872SA
Inventor
Oi Kwan Wong
Joyce Ching Chou
Mathilde Brunnhilde DUSSEAUX
Julianne Smith
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SG11201805872SA publication Critical patent/SG11201805872SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 1111111101111011101010111110101111101110111011110111111111101111101111011111 International Bureau ... ..51 jd (10) International Publication Number ..... ..... ..r .,,,i (43) International Publication Date WO 2017/125830 Al 27 July 2017 (27.07.2017) WIPO I PCT (51) International Patent Classification: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, C07K 14/47 (2006.01) C07K 16/28 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, A61K 38/00 (2006.01) C07K 16/30 (2006.01) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, A61K 48/00 (2006.01) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (21) International Application Number: RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, PCT/IB2017/050108 TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (22) International Filing Date: ZA, ZM, ZW. 10 January 2017 (10.01.2017) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (26) Publication Language: English TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (30) Priority Data: TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, 62/281,533 21 January 2016 (21.01.2016) US DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 62/431,758 8 December 2016 (08.12.2016) US LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, GW, KM, ML, MR, NE, SN, TD, TG). New York, NY 10017 (US). Declarations under Rule 4.17: (72) Inventors: WONG, Oi Kwan; 15 Arroyo View Circle, — as to the identity of the inventor (Rule 4.17(i)) Belmont, CA 94002 (US). CHOU, Joyce Ching; 767 — Silkoak Way, Sunnyvale, CA 94086 (US). DUSSEAUX, — as to applicant's entitlement to apply for and be granted a — Mathilde Brunnhilde; 19 domaine de Chateau, _ Gaillard, patent (Rule 4.17(ii)) 1675 as to the applicant's entitlement to claim the priority of the = 94700 Maisons-Alfort (FR). SMITH, Julianne; application (Rule 4.17(iii)) York Avenue, New York (US). , NY 10128 —earlier East 42nd Published: (74) Agent: WALDRON, Roy F.; Pfizer Inc., 235 Street, MS 235/9/S20, New York, NY 10017 = (US). — with international search report (Art. 21(3)) for every (81) Designated States (unless otherwise indicated, kind AE, AG, AL, AM, with sequence listing part of description (Rule 5.2(a)) of national protection available): AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, DJ, DK, DM, = BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, = = = = = TARGETING EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III (54) Title: CHIMERIC ANTIGEN RECEPTORS = 'IA HG. loo 80 - N. M F98 (EGFR Negative) 1-1 60 40 en 20 GO ir) 0 I -7) „..,. n F98 -EGFRwt Ei F98 -EGFRvill ell 0 10 2 10 3 10 4 10 5 - IN 1-1 (57) : The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRv111 (Epidermal Growth N Factor Receptor Variant III). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nude - ic acids, and methods of making thereof, engineered immune cells, and nucleic acids. The invention further relates to therapeutic C methods for using these CARs and engineered immune cells for the treatment of EGFRv111-mediated pathologies, including cancers such as glioblastoma.
SG11201805872SA 2016-01-21 2017-01-10 Chimeric antigen receptors targeting epidermal growth factor receptor variant iii SG11201805872SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662281533P 2016-01-21 2016-01-21
US201662431758P 2016-12-08 2016-12-08
PCT/IB2017/050108 WO2017125830A1 (en) 2016-01-21 2017-01-10 Chimeric antigen receptors targeting epidermal growth factor receptor variant iii

Publications (1)

Publication Number Publication Date
SG11201805872SA true SG11201805872SA (en) 2018-08-30

Family

ID=57868301

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201805872SA SG11201805872SA (en) 2016-01-21 2017-01-10 Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
SG10202111458RA SG10202111458RA (en) 2016-01-21 2017-01-10 Chimeric antigen receptors targeting epidermal growth factor receptor variant iii

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202111458RA SG10202111458RA (en) 2016-01-21 2017-01-10 Chimeric antigen receptors targeting epidermal growth factor receptor variant iii

Country Status (22)

Country Link
US (3) US10259876B2 (en)
EP (1) EP3405481B1 (en)
JP (2) JP6823659B2 (en)
KR (1) KR102479606B1 (en)
CN (1) CN108699124A (en)
AU (1) AU2017208834B2 (en)
BR (1) BR112018014585A2 (en)
CA (1) CA2954014A1 (en)
DK (1) DK3405481T5 (en)
EA (1) EA201891641A1 (en)
ES (1) ES2942362T3 (en)
IL (1) IL260666B2 (en)
MX (1) MX2018008978A (en)
MY (1) MY192474A (en)
NZ (1) NZ744821A (en)
PH (1) PH12018501473B1 (en)
RU (1) RU2751662C2 (en)
SA (1) SA518392058B1 (en)
SG (2) SG11201805872SA (en)
TW (2) TWI634125B (en)
UA (1) UA125252C2 (en)
WO (1) WO2017125830A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108472365A (en) 2015-10-30 2018-08-31 艾丽塔生物治疗剂公司 Compositions and methods for tumor transduction
MX2018005315A (en) * 2015-10-30 2018-08-14 Aleta Biotherapeutics Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER.
DK3405490T3 (en) 2016-01-21 2022-01-10 Pfizer MONO- AND BISPECIFIC ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III AND CD3 AND USES THEREOF
SG11201805872SA (en) * 2016-01-21 2018-08-30 Pfizer Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
US11590167B2 (en) 2016-12-03 2023-02-28 Juno Therapeutic, Inc. Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
CN111225675B (en) 2017-06-02 2024-05-03 朱诺治疗学股份有限公司 Articles and methods of treatment using adoptive cell therapy
EP3773632A4 (en) 2018-04-06 2022-05-18 The Regents of The University of California METHODS OF TREATMENT OF EGFRVIII-EXPRESSING GLIOBLASTOMAS
EP3773633A4 (en) 2018-04-06 2022-01-26 The Regents of The University of California GLIOBLASTOMA TREATMENT METHODS
JP2021532742A (en) * 2018-07-26 2021-12-02 ナンジン レジェンド バイオテック カンパニー, リミテッドNanjing Legend Biotech Co., Ltd. T cells containing NEF and their production methods
CN109265561B (en) * 2018-09-25 2021-05-25 山东兴瑞生物科技有限公司 Anti-EGFRvIII safe chimeric antigen receptor, its preparation method, NK cells modified by the same and its application
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
JP7630832B2 (en) * 2018-11-19 2025-02-18 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Modular polycistronic vectors for CAR and TCR transduction
MX2021006395A (en) * 2018-12-01 2021-07-15 Allogene Therapeutics Inc Chimeric antigen receptors targeting b-cell maturation antigen and methods of use thereof.
MX2021007307A (en) * 2018-12-21 2021-07-07 Hoffmann La Roche Antibodies binding to cd3.
BR112021014031A2 (en) * 2019-01-17 2021-09-21 Immunocore Limited PHARMACEUTICAL FORMULATION, USE OF FORMULATION, AND METHOD OF PREPARING AN AQUEOUS PHARMACEUTICAL FORMULATION
CN111454358A (en) * 2019-01-18 2020-07-28 四川科伦博泰生物医药股份有限公司 A kind of chimeric antigen receptor and its application
WO2020190771A1 (en) * 2019-03-15 2020-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric adaptor and kinase signaling proteins and their use in immunotherapy
EP3994173A1 (en) * 2019-07-02 2022-05-11 The United States of America, as represented by the Secretary, Department of Health and Human Services Monoclonal antibodies that bind egfrviii and their use
WO2021022044A1 (en) * 2019-07-31 2021-02-04 Forty Seven, Inc. Depletion regimes for engineered t-cell or nk-cell therapy
US20220401537A1 (en) * 2019-09-16 2022-12-22 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
CN115175736A (en) * 2019-10-01 2022-10-11 艾普西洛根有限公司 Hybrid antibodies
WO2021130250A1 (en) * 2019-12-23 2021-07-01 Cellectis New mesothelin specific chimeric antigen receptors (car) for solid tumors cancer immunotherapy
JP2023515747A (en) * 2019-12-28 2023-04-14 シャンハイ セル セラピー グループ カンパニー カンパニー リミテッド Cells expressing immunomodulatory molecules and systems for expressing immunomodulatory molecules
CN111019959B (en) * 2019-12-30 2022-09-13 北京立康生命科技有限公司 Nucleotide molecule for in vitro transcription of mRNA, presenting cell and application
US20230147832A1 (en) * 2020-01-22 2023-05-11 City Of Hope Oncolytic virus compositions including il-15 complex and methods for the treatment of cancer
WO2022140388A1 (en) 2020-12-21 2022-06-30 Allogene Therapeutics, Inc. Protease-activating cd45-gate car
CA3204417A1 (en) 2021-01-29 2022-08-04 Allogene Therapeutics, Inc. Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products
US20250121002A1 (en) * 2021-07-16 2025-04-17 Noile-Immune Biotech Inc. ANTI-EGFRviii ANTIBODY, POLYPEPTIDE, CELL CAPABLE OF EXPRESSING SAID POLYPEPTIDE, PHARMACEUTICAL COMPOSITION COMPRISING SAID CELL, METHOD FOR PRODUCING SAID CELL, AND POLYNUCLEOTIDE OR VECTOR COMPRISING NUCLEOTIDE SEQUENCE ENCODING SAID POLYPEPTIDE
JP2024539550A (en) * 2021-09-29 2024-10-29 ナショナル リサーチ カウンシル オブ カナダ Humanized anti-EGFR VIII antibodies and antigen-binding fragments thereof
EP4562134A1 (en) 2022-07-29 2025-06-04 Allogene Therapeutics, Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
JP2025525941A (en) * 2022-08-05 2025-08-07 北京鼎成▲タイ▼源生物技術有限公司 Antibodies targeting egfrviii and their use in cellular immunotherapy
CN116284435A (en) * 2022-09-19 2023-06-23 卡瑞济(北京)生命科技有限公司 EGFRvIII chimeric antigen receptor and uses thereof
US20240325532A1 (en) * 2023-03-30 2024-10-03 Novocure Gmbh Compositions, systems, and methods for treating cancer using tumor treating fields and chimeric antigen receptor (car)-immune cells
WO2025096560A1 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Engineered cells
CN117659196B (en) * 2023-12-12 2024-08-23 成都优赛诺生物科技有限公司 CD 7-targeted single domain antibody, chimeric antigen receptor and application thereof
CN119912588B (en) * 2025-04-01 2025-08-12 浙江大学 Chimeric antigen receptor, human induced pluripotent stem cells, myeloid precursor cell-like macrophages and preparation methods thereof
CN120248142B (en) * 2025-06-06 2025-09-12 上海兴瑞一达生物科技有限公司 A dual-target chimeric antigen receptor co-expressing CD47 and IL-15, CAR-T cell and its application

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69127627T2 (en) 1990-08-29 1998-02-19 Genpharm Int Production and Use Non-human transgene heterologous antibodies for production
DE69129154T2 (en) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES
ATE348175T1 (en) 1992-07-17 2007-01-15 Dana Farber Cancer Inst Inc METHOD OF INTRACELLULAR BINDING OF TARGETED MOLECULES
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
ATE373078T1 (en) 2000-02-24 2007-09-15 Xcyte Therapies Inc SIMULTANEOUS STIMULATION AND CONCENTRATION OF CELLS
PL357448A1 (en) * 2000-02-25 2004-07-26 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services Anti-egfrviii scfvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
WO2008045437A2 (en) 2006-10-09 2008-04-17 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
US20130337454A1 (en) 2010-10-27 2013-12-19 Philippe Duchateau Method for increasing the efficiency of double-strand break-induced mutagenesis
US9249217B2 (en) 2010-12-03 2016-02-02 Secretary, DHHS Bispecific EGFRvIII x CD3 antibody engaging molecules
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9266960B2 (en) 2011-04-08 2016-02-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
US20150017136A1 (en) 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
JP6154895B2 (en) 2012-06-07 2017-06-28 デューク ユニバーシティー Human bispecific EGFRvIII antibody binding molecule
MX2015000426A (en) * 2012-07-13 2015-07-14 Univ Pennsylvania Enhancing activity of car t cells by co-introducing a bispecific antibody.
CN104769103B (en) 2012-09-04 2018-06-08 塞勒克提斯公司 Multi-chain chimeric antigen receptors and uses thereof
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
HUE046961T2 (en) * 2013-02-20 2020-04-28 Univ Pennsylvania Treatment of cancer using a chimeric antigen receptor against humanized EGFRVIII
ES2790420T3 (en) 2013-03-14 2020-10-27 Scripps Research Inst Conjugates of antibodies and targeting agents uses of the same
AU2014266833B2 (en) 2013-05-13 2020-07-02 Cellectis Methods for engineering highly active T cell for immunotherapy
EP4364809A3 (en) 2013-05-13 2024-07-24 Cellectis Cd19 specific chimeric antigen receptor and uses thereof
ES2645393T3 (en) 2013-05-29 2017-12-05 Cellectis T lymphocyte manipulation methods for immunotherapy using the RNA-guided Cas nuclease system
ES2718399T3 (en) 2013-07-09 2019-07-01 Univ Duke Molecules that attach to human bispecific EGFRVIII antibodies
HUE054057T2 (en) 2013-08-07 2021-08-30 Affimed Gmbh Antibody binding sites specific for egfrviii
JP2017504601A (en) * 2013-12-20 2017-02-09 セレクティスＣｅｌｌｅｃｔｉｓ Method for manipulating multi-input signal sensitive T cells for immunotherapy
WO2016016341A1 (en) * 2014-07-29 2016-02-04 Cellectis EGFRvIII SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY
TWI744242B (en) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Antibody constructs for egfrviii and cd3
DK3405490T3 (en) 2016-01-21 2022-01-10 Pfizer MONO- AND BISPECIFIC ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III AND CD3 AND USES THEREOF
SG11201805872SA (en) 2016-01-21 2018-08-30 Pfizer Chimeric antigen receptors targeting epidermal growth factor receptor variant iii

Also Published As

Publication number Publication date
US20170210811A1 (en) 2017-07-27
SA518392058B1 (en) 2023-02-12
ES2942362T3 (en) 2023-05-31
PH12018501473B1 (en) 2023-08-02
EP3405481A1 (en) 2018-11-28
PH12018501473A1 (en) 2019-03-11
US10259876B2 (en) 2019-04-16
MX2018008978A (en) 2019-01-10
JP2021036873A (en) 2021-03-11
KR20180099890A (en) 2018-09-05
MY192474A (en) 2022-08-23
RU2751662C2 (en) 2021-07-15
TW201734038A (en) 2017-10-01
AU2017208834B2 (en) 2021-09-02
AU2017208834A1 (en) 2018-08-09
DK3405481T5 (en) 2024-09-23
UA125252C2 (en) 2022-02-09
SG10202111458RA (en) 2021-11-29
JP7198797B2 (en) 2023-01-04
US20220227874A1 (en) 2022-07-21
RU2018130088A3 (en) 2020-07-29
NZ744821A (en) 2023-06-30
US20190144550A1 (en) 2019-05-16
US11267892B2 (en) 2022-03-08
CA2954014A1 (en) 2017-07-21
IL260666B2 (en) 2023-02-01
DK3405481T3 (en) 2023-04-17
EA201891641A1 (en) 2019-01-31
WO2017125830A1 (en) 2017-07-27
BR112018014585A2 (en) 2018-12-11
EP3405481B1 (en) 2023-01-18
TWI755547B (en) 2022-02-21
TWI634125B (en) 2018-09-01
JP6823659B2 (en) 2021-02-03
KR102479606B1 (en) 2022-12-21
CN108699124A (en) 2018-10-23
TW201920237A (en) 2019-06-01
IL260666B (en) 2022-10-01
IL260666A (en) 2018-09-20
RU2018130088A (en) 2020-02-25
JP2019506394A (en) 2019-03-07

Similar Documents

Publication Publication Date Title
SG11201805872SA (en) Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
SG11201807489PA (en) Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201811290VA (en) Compositions and methods for the depletion of cd117+cells
SG11201811432WA (en) Rna for cancer therapy
SG11201907580SA (en) Combination therapies for treatment of bcma-related cancers and autoimmune disorders
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201803676PA (en) Site specific her2 antibody drug conjugates
SG11201908023YA (en) T cell receptors and immune therapy using the same against prame positive cancers
SG11201900468YA (en) Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201804038VA (en) Conditionally active heterodimeric polypeptides and methods of use thereof
SG11201905812WA (en) Azolopyrimidine for the treatment of cancer-related disorders
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201901126UA (en) Combination therapy for cancer
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201908598PA (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
SG11201811292RA (en) Compositions and methods for the depletion of cells
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201808125RA (en) Methods for solid tumor treatment
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201810801QA (en) Brain delivery protein
SG11201900361RA (en) Methods of treating prostate cancer